https://draigtherapeutics.com/research-news/draig-therapeutics-to-present-at-the-american-society-for-clinical-psychopharmacology-ascp-annual-meeting/ 2026-05-19T12:22:04+00:00 https://draigtherapeutics.com/research-news/draig-therapeutics-to-participate-in-the-stifel-2026-virtual-cns-forum/ 2026-05-19T12:22:04+00:00 https://draigtherapeutics.com/research-news/draig-therapeutics-appoints-seasoned-neuroscience-leader-ivana-magovcevic-liebisch-as-president-and-chief-executive-officer/ 2026-05-19T12:22:04+00:00 https://draigtherapeutics.com/research-news/draig-therapeutics-announces-us-fda-clearance-of-ind-application-for-phase-2-study-of-dt-101-for-the-treatment-of-major-depressive-disorder/ 2026-05-19T12:22:04+00:00 https://draigtherapeutics.com/research-news/draig-therapeutics-appoints-experienced-biotech-leader-douglas-e-williams-ph-d-as-chair-of-its-board-of-directors/ 2026-05-19T12:22:04+00:00 https://draigtherapeutics.com/research-news/draig-therapeutics-launches-with-140-million-107-million-total-investment-to-advance-its-portfolio-of-next-generation-therapies-for-major-neuropsychiatric-disorders/ 2026-05-19T12:22:04+00:00